What is Wedbush’s Forecast for Disc Medicine Q4 Earnings?

Disc Medicine, Inc. (NASDAQ:IRON) – Research analysts at Wedbush decreased their Q4 2024 earnings estimates for Disc Medicine in a note issued to investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.94) per share for the quarter, down from their prior estimate of ($0.89). Wedbush has a “Outperform” rating and a $83.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.15) per share. Wedbush also issued estimates for Disc Medicine’s Q1 2025 earnings at ($0.98) EPS, Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.10) EPS, FY2026 earnings at ($4.19) EPS and FY2027 earnings at $2.20 EPS.

A number of other equities research analysts have also recently commented on the company. Wells Fargo & Company initiated coverage on Disc Medicine in a research note on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 price target for the company. HC Wainwright lifted their target price on shares of Disc Medicine from $70.00 to $118.00 and gave the stock a “buy” rating in a research note on Wednesday. Scotiabank boosted their target price on shares of Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 5th. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $66.00 to $110.00 in a report on Monday, November 4th. Finally, Morgan Stanley raised shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective on the stock in a report on Tuesday, November 5th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Disc Medicine presently has an average rating of “Buy” and a consensus target price of $85.80.

Disc Medicine Trading Down 2.0 %

Shares of IRON opened at $59.46 on Friday. The firm has a market cap of $1.77 billion, a PE ratio of -14.94 and a beta of 0.60. Disc Medicine has a 12 month low of $25.60 and a 12 month high of $77.60. The stock has a fifty day moving average price of $51.20 and a 200-day moving average price of $44.97.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.15.

Insider Buying and Selling at Disc Medicine

In other news, Director William Richard White sold 7,136 shares of the business’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $58.61, for a total value of $418,240.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 7,538 shares of company stock valued at $437,875. 4.24% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Swiss National Bank increased its holdings in shares of Disc Medicine by 50.6% during the 1st quarter. Swiss National Bank now owns 23,800 shares of the company’s stock valued at $1,482,000 after purchasing an additional 8,000 shares in the last quarter. ProShare Advisors LLC acquired a new position in shares of Disc Medicine in the first quarter worth about $211,000. Bleakley Financial Group LLC boosted its stake in shares of Disc Medicine by 23.0% during the 1st quarter. Bleakley Financial Group LLC now owns 4,572 shares of the company’s stock worth $285,000 after acquiring an additional 856 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in shares of Disc Medicine during the 1st quarter valued at about $7,429,000. Finally, Vanguard Group Inc. increased its stake in shares of Disc Medicine by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 782,751 shares of the company’s stock valued at $48,734,000 after purchasing an additional 18,207 shares in the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.